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those nuclei typical of the period before nuclear testing
began; cortical neurons from people born later have 14C
levels that match those in the atmosphere at the time
of their birth. This reinforces the longstanding view that
the life span of neurons in the human cerebral cortex
can be a century or more.
The Spalding et al. (2005) study enables a more direct
understanding of cell turnover, aging, and life span
throughout the human body and those of other long-
lived animals. This, in turn, informs our understanding
of human developmental and regenerative biology. Such
knowledge will be instrumental in developing cellular
replacement therapies to treat damaged and diseased
tissues.
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MicroRNAs (miRNAs) are known to regulate the ex- t
pression of genes involved in the control of develop- 5
ment, proliferation, apoptosis, and the stress response. E
As a cluster of recent Nature papers now show, al- o
tered expression of specific miRNA genes contrib- c
Eutes to the initiation and progression of cancer.MicroRNAs (miRNAs) are short 20–22 nucleotide RNA
molecules that are negative regulators of gene expres-
sion in a variety of eukaryotic organisms. These RNA
molecules are produced from larger transcripts that are
processed to form hairpin precursors that serve as sub-
strates for Drosha and Dicer, members of the RNase
III enzyme family. These enzymes work sequentially to
generate mature 20–22 nucleotide miRNAs from the
hairpin precursors (reviewed in He and Hannon, 2004).
In animal cells, single-stranded miRNAs bind to spe-
cific target mRNAs through partly complementary se-
quences that are predominantly in the 3# untranslated
region (3#UTR). The bound mRNAs either remain un-
translated resulting in a decrease in the proteins they
encode or are degraded by the RNA interference effec-
tor complex (RISC) resulting in a decreased number of
transcripts (reviewed in Bartel, 2004). miRNAs are in-
volved in numerous cellular processes including devel-
opment, differentiation, proliferation, apoptosis, and
the stress response. Studies from the last three years
have demonstrated that there is altered expression of
miRNA genes in several human malignancies, including
chronic lymphocytic leukemia, pediatric Burkitt’s lym-
phoma, gastric cancer, lung cancer, and large cell lym-
phoma (reviewed in McManus, 2003 and Gregory and
Shiekhattar, 2005). Now, three new studies published in
Nature confirm that altered expression of specific miRNAs
is involved in tumorigenesis, while a fourth reveals that
miRNAs may be important for enabling stem cells to
overcome the G1/S checkpoint of the cell cycle.
It is well established that a cluster of miRNAs, the
miR-17-92 polycistron, is located on chromosome
13q32-33 in a region that is amplified in follicular lym-
phoma, a low-grade B cell malignancy. Using microar-
ray analysis of B cell lymphoma samples and a mouse
model of B cell lymphoma generated by activation of the
Myc oncogene, He et al. (2005) investigated whether the
miR-17-92 cluster of miRNAs cooperates with Myc to
promote tumor development. First, the authors show
that there is increased expression of the miR-17-92
cluster in B cell lymphomas compared to normal tissue
samples. Next they demonstrate that enforced expres-
sion of the miR-17-92 cluster cooperates with upregu-
lated Myc expression to promote formation of B cell
lymphomas in the mouse. Tumors exhibiting upregula-
tion of certain members of the miRNA cluster and Myc
showed an absence of apoptosis, a phenomenon com-
monly observed in Myc-induced lymphomas. It will be
of interest to determine whether another miRNA, miR-
55, also promotes tumor development because over-
xpression and amplification of miR-155 is observed in
ediatric Burkitt’s lymphoma (Metzler et al., 2004) and
arge cell lymphomas (Eis et al., 2005).
A companion study by O’Donnell et al. (2005) also
nvestigated the interaction between the miR-17-92
luster and Myc. These authors reveal that Myc binds
irectly to the miR-17-92 locus on chromosome 13 and
ctivates expression of the miRNA cluster. In addition,
hey show that two miRNAs from this cluster, miR-17-
p and miR-20a, negatively regulate expression of the
2F1 transcription factor. E2F1 is an additional target
f Myc that promotes cell-cycle progression. Their dis-
overy reveals a mechanism by which Myc activates
2F1-mediated transcription yet decreases its transla-
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proliferative signal. Given that Myc activates expres-
sion of the miRNA cluster at chromosome 13q32-33, it
will be interesting to determine how this cluster accel-
erates the development of Myc-induced lymphomas,
as He et al. report.
In their Nature paper, Lu et al. (2005) describe a new
bead-based flow cytometric technique for obtaining
miRNA expression profiles. Using this technique, Lu
and colleagues analyzed the expression of 217 miRNAs
in 332 tissue samples, including many different types
of tumors. Glass-slide microarrays have been used for
miRNA expression profiling, but there have been con-
cerns about crosshybridization of related miRNAs. To
overcome this problem, Lu and coworkers developed a
bead-based profiling method in which oligonucleotide-
capture probes each complementary to a single miRNA
are coupled to polystyrene beads tagged with different
mixtures of fluorescent dyes. After amplification by
polymerase chain reaction (PCR) using a biotinylated
primer, the miRNAs are hybridized to the capture
beads, stained with streptavidin-phycoerythrin, and an-
alyzed by flow cytometry. When compared to glass-
slide microarrays, this approach has the advantage of
liquid hybridization kinetics; however, the disadvantage
may be in scaling up the procedure to process many
more samples. The miRNA profiles obtained by Lu et
al. are informative, reflecting the lineage and differentia-
tion status of the tumor. The results show that even in
leukemias of a single hematopoietic lineage there are
distinct patterns of miRNA expression that reflect dif-
ferent mechanisms of malignant transformation. Thus,
this approach could be used to distinguish different
types of acute leukemias of the same hematopoietic
cell lineage. However, surprisingly, overall miRNA ex-
pression tended to be downregulated in tumors com-
pared with normal tissues. This result is unexpected as
not only downregulation of miRNAs, such as miR-15
and miR-16, but also upregulation of other miRNAs,
such as miR-155, is known to occur in many human
tumors. In fact, meta-analyses of miRNA expression
profiles in different human solid tumors, including those
of breast, colon, stomach, pancreas, lung, and thyroid,
indicate overexpression of several miRNAs. Thus, the
new profiling method developed by Lu et al. needs to
be expanded to include a greater variety of tumor
types. It would be useful if the authors compared their
new miRNA expression profiling method to other ge-
nome-wide methods for analyzing miRNA expression.
It is clear that miRNA expression profiling of human ma-
lignancies will be of value for diagnosis and prognosis
in the clinic.
Finally, in a separate but related Nature paper, Hat-
field et al. (2005) reveal that stem cell division in the fruit
fly Drosophila melanogaster is regulated by the miRNA
pathway. A key characteristic of stem cells is that they
can divide for long periods of time in an environment
where most other cells are quiescent, prompting the
question of how they overcome the G1/S checkpoint of
the cell cycle. Hatfield et al. used fruit fly germline stem
cells carrying a mutation in dicer-1, a gene essential for
miRNA biogenesis, to show that miRNAs are required
for stem cells to bypass the G1/S checkpoint. This sug-
gests that miRNAs may be involved in the mechanismthat makes stem cells insensitive to environmental
stimuli that would normally halt most cells at the G1/S
checkpoint. The implication is that the mechanism
used by stem cells to overcome this checkpoint could
possibly be usurped by tumor cells.
The cluster of Nature papers clearly indicate that
overexpression of miRNA genes is important in the de-
velopment of cancer. Changes in miRNA gene expres-
sion between tumor tissues and their normal counter-
parts could be exploited, not only for diagnostic and
prognostic purposes in the clinic but also to investigate
the specific roles of the various miRNAs in tumor devel-
opment and to identify the genes and pathways that
they target. Altered expression of miRNA genes may
be related to the specific genetic alterations, such as
deletions and amplifications, that frequently occur in
human tumors. Since changes in gene expression can
be either primary or secondary events, it will be impor-
tant to define those genetic alterations in miRNA genes
that may contribute to tumorigenesis. Given that miRNAs
regulate gene expression and enter readily into cells,
they have potential as therapeutics to treat cancer and
other human diseases. Before this step can be taken,
however, important questions remain to be answered.
For example, which mechanisms regulate miRNA gene
expression under normal conditions and which go awry
during tumorigenesis? It will be important to determine
whether germline alterations in miRNA genes or miRNA
precursor molecules are involved in cancer or other hu-
man diseases.
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